Mr. Marcos Agramont reports

ISODIOL INTERNATIONAL INC. APPLAUDS THE U.K. GOVERNMENT'S DECISION TO LEGALIZE MEDICAL CANNABIS

Isodiol International Inc. is applauding the government of the United Kingdom on its decision to legalize medical cannabis and allow expert doctors to have an option to prescribe cannabis-based medicines in England, Whales and Scotland. The new law will not limit the types of conditions that can be considered and no longer will patients be required to seek approval from an expert panel.

"This is a historical change for the people of the United Kingdom," said Marcos Agramont, chief executive officer of Isodiol. "While this rescheduling of cannabis-based medicinal products doesn't pave the path toward legalizing cannabis for recreational use, beginning Nov. 1, thousands of patients with a wide range of medical conditions will now have a new option that may benefit their health." Isodiol's wholly owned United Kingdom subsidiary, BSPG Laboratories, received approval from the MHRA (Medicines and Healthcare products Regulatory Agency) in the United Kingdom to manufacture a pure, natural cannabidiol (CBD) molecule in April, 2018, as an active pharmaceutical ingredient (API). CBD derived from cannabis has been shown to be effective for a wide range of medical conditions, including, but not limited to, epilepsy, cancer, pain, Parkinson's disease and fibromyalgia.

BSPG Laboratories operates a GMP-compliant (good manufacturing practice) facility and focuses on cannabinoids for scientific and pharmaceutical applications as well as research and clinical studies. The company also manufactures CBD-based specials that are sold in the United Kingdom, Brazil and various other markets. Specials are products that have been specially manufactured for the treatment of an individual patient after being ordered by a doctor.

"As governments across the globe continue to recognize the medicinal value of cannabis and the regulations change, the company believes the acquisition of BSPG Labs will continue to be validated. BSPG Labs is positioned to supply the new demand that will be created for cannabis-based CBD medicines," added Mr. Agramont.

About Isodiol International Inc.

Isodiol is a market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and it will aggressively continue international expansion into Latin America, Asia and Europe.

We seek Safe Harbor.